UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025#UNITY #Biotechnology #Host #Virtual #Investor #Event #Discuss #36Week #Data #Phase #ASPIRE #Study #UBX1325 #Patients #Diabetic #Macular #Edema #DME #March